Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Orange, California and other locations
Dates
study started
completion around

Description

Summary

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

Official Title

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants with KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

Keywords

Advanced Solid Tumors with KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer, KRAS G12C, Pancreatic Cancer, Neoplasms, FMC-376

Eligibility

Locations

  • University of California Irvine (UCI) - Chao Family Comprehensive Cancer Center accepting new patients
    Orange California 92868 United States
  • University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center accepting new patients
    La Jolla California 92037 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Frontier Medicines Corporation
ID
NCT06244771
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 403 study participants
Last Updated